Want to see ALNY full AI Analyst Report?
ALNY Stock Chart & Stats
$240.08
$10.57(3.89%)
At close: 4:00 PM EDT
$240.08
$10.57(3.89%)
Day’s Range― - ―
52-Week Range$197.81 - $495.55
Previous CloseN/A
Volume740.62K
Average Volume (3M)1.54M
Market Cap
$34.25B
Enterprise Value$41.31K
Total Cash (Recent Filing)$3.31B
Total Debt (Recent Filing)$1.27B
Price to Earnings (P/E)42.0
Beta0.93
Next Earnings
Oct 29, 2026EPS Estimate
1.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.10
Shares Outstanding133,809,110
10 Day Avg. Volume1,352,128
30 Day Avg. Volume1,544,024
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)66.01
Price to Sales (P/S)14.03
P/FCF Ratio111.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$368.22Price Target Upside53.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)6.72
Revenue Forecast (FY)$5.46B
Bulls Say, Bears Say
Bulls Say
Strong Product GrowthRapid growth in marketed product revenue shows strong commercial adoption and expanding demand for Alnylam’s RNAi medicines. If sustained, this scale can support broader geographic reach, strengthen the commercial franchise, and provide more resources for pipeline investment.
Robust Cash GenerationHigh operating and free cash flow indicates that recent profitability is converting into usable cash rather than remaining primarily accounting-based. This supports clinical development, commercialization, and balance-sheet strengthening while reducing reliance on external financing.
Expanding Commercial FranchiseA growing prescriber base and strong share of new patient starts indicate increasing physician adoption of AMVUTTRA and broader commercial reach. These trends can support durable patient growth and reinforce Alnylam’s position in RNAi-based TTR treatment.
Bears Say
Lower TTR GuidanceThe guidance reduction shows that initial launch demand was partly boosted by temporary pent-up switching activity, making near-term growth less predictable. Although the revised outlook still implies strong expansion, normalization raises execution risk for sustaining the franchise’s growth rate.
Royalty-driven Margin PressureHigher royalty rates mean incremental product revenue contributes less gross profit, directly limiting operating leverage as AMVUTTRA scales. Persistent royalty pressure could reduce the cash available for research and commercialization unless volume growth or other efficiencies offset the burden.
Rising Operating InvestmentLarge increases in R&D and SG&A reflect substantial spending needed to advance trials and support launches. These investments may build future growth, but they also raise the revenue threshold required to preserve margins and increase earnings volatility if programs or launches underperform.
Alnylam Pharma News
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $197.81 and its highest was $495.55 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $34.25B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 31 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Jul 30, 2026. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.63 by -$0.42.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 1.78.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 133,809,110 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of $1.21 in its last earnings report, missing expectations of $1.63. Following the earnings report the stock price went down -28.309%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in ALNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alnylam Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$368.22 (53.37% Upside)
$368.22 (53.37% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 69%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Decreased
By 25.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
ALNY Company Deck
ALNY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum — highlighted by record quarterly AMVUTTRA and broad TTR revenue growth, expanding prescriber base, robust cash and operating income, strategic geographic and AI partnerships, and an active pipeline with upcoming data readouts. Negative elements included a $200M downward revision to 2026 TTR guidance tied to normalization of early switch demand, a Q2 decline in collaboration revenue, margin pressure from higher royalties, increased R&D/SG&A investment, and industry uncertainty following a competitor trial failure (CARDIO-TTRansform). Management framed the guidance reduction as a learning from early launch dynamics and emphasized confidence in long-term TTR leadership and nucresiran’s prospects, indicating highlights outweigh challenges.View all ALNY earnings summariesALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
ALNY Stock 12 Month Forecast
Average Price Target
$368.22
▲(53.37% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Ownership Overview
0.26% Insiders
45.01% Mutual Funds
23.93% Other Institutional Investors
8.13% Public Companies and Individual Investors